Overseas acquisitions: Indian drugmakers shop for deals abroad as they move away from generics

Global uncertainties over the past two years, including US President Donald Trump’s tariff threats, price erosion in the generics market, and a Big Pharma shift towards biologics are forcing Indian drugmakers to seek new avenues of growth.